STARPHARMA HOLDINGS LIMITED (SPL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SPL - STARPHARMA HOLDINGS LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.36
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.097

17 Jul
2024

-0.003

OPEN

$0.10

-3.00%

HIGH

$0.10

460,065

LOW

$0.10

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-3.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx2.9 M
Book Value Per Share xxxxxxxxxxxxxxx8.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-13.5 M
Net Profit Margin xxxxxxxxxxxxxxx-532.09 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-37.59 %
Return on Invested Capital xxxxxxxxxxxxxxx-33.47 %
Return on Assets xxxxxxxxxxxxxxx-26.45 %
Return on Equity xxxxxxxxxxxxxxx-37.59 %
Return on Total Capital xxxxxxxxxxxxxxx-49.51 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-14.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx6 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx35 M
Price To Book Value xxxxxxxxxxxxxxx3.66

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.6 M
Capex % of Sales xxxxxxxxxxxxxxx21.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx26 M
Research & Development xxxxxxxxxxxxxxx19 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

SPL STOCK CHART